Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine

[1]  J. Hare.  Nitroso-redox balance in the cardiovascular system. , 2004, The New England journal of medicine.

[2]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[3]  S. Yusuf,et al.  Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study , 2003, The Lancet.

[4]  Takahiro Hayashi,et al.  Long-term, Continuous Treatment with Both Oral and Transdermal Nitrates Increases Cardiac Events in Healed Myocardial Infarction Patients , 2002, Angiology.

[5]  Takahiro Hayashi,et al.  Continuous long‐term dosing with oral slow‐release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction , 2001, Clinical cardiology.

[6]  C. Chiueh,et al.  Effects of Atypical Antioxidative Agents, S‐nitrosoglutathione and Manganese, on Brain Lipid Peroxidation Induced by Iron Leaking from Tissue Disruption , 2000, Annals of the New York Academy of Sciences.

[7]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[8]  S. Rajagopalan,et al.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.

[9]  U. Elkayam.  Prevention of nitrate tolerance with concomitant administration of hydralazine. , 1996, The Canadian journal of cardiology.

[10]  U. Elkayam,et al.  Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. , 1995, Journal of the American College of Cardiology.

[11]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[12]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[13]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[14]  J. Bauer,et al.  Concurrent Hydralazine Administration Prevents Nitroglycerin‐Induced Hemodynamic Tolerance in Experimental Heart Failure , 1991, Circulation.

[15]  Thomas M. Ludden,et al.  Nonlinear Pharmacokinetics , 1991, Clinical pharmacokinetics.

[16]  M. Relling.  Polymorphic drug metabolism. , 1989, Clinical pharmacy.

[17]  T. Ludden,et al.  Relative bioavailability of immediate- and sustained-release hydralazine formulations. , 1988, Journal of pharmaceutical sciences.

[18]  C. Mulrow,et al.  Relative efficacy of vasodilator therapy in chronic congestive heart failure. Implications of randomized trials. , 1988, JAMA.

[19]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[20]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[21]  M. Crawford,et al.  Determinants of systemic availability of oral hydralazine in heart failure , 1985, Clinical pharmacology and therapeutics.

[22]  T. Ludden,et al.  Effect of oral dose size on hydralazine kinetics and vasodepressor response , 1984, Clinical pharmacology and therapeutics.

[23]  J. Cohn,et al.  Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. , 1982, American heart journal.

[24]  J. Parker,et al.  Kinetics of isosorbide dinitrate and relationships to pharmacological effects. , 1981, British journal of clinical pharmacology.

[25]  D. Drayer,et al.  Hydralazine elimination in man , 1973, Clinical pharmacology and therapeutics.